Is the oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?

American Surgeon

Volumn 77, Issue 10, 2011, Pages 1364-1367

  Lee, Jenny J ^a   Shen, Jeannie ^a  

^a HUNTINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ASSAY; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; HUMAN; LYMPH VESSEL; MAJOR CLINICAL STUDY; NODE STATUS; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 80755159061     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Buetow K, Klausner R, Fine H, et al. Cancer molecular analysis project: weaving a rich cancer research tapestry. Cancer Cell 2002;1:315-8. (Pubitemid 41039133)
2. Hahn W, Weinberg R. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603, [Erratum, N Engl J Med 2003; 348:674]. (Pubitemid 35315841)
3. Paik S, Shak S, Kim C, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
4. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84. (Pubitemid 19062522)
5. Fisher B, Jeong J, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-68. (Pubitemid 39221063)
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
7. Lo S, Mumby P, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-6.
8. Albain K, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009;18:S141-5.
9. Tsoi D, Inoue M, Kelly C, et al. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010;15:457-65.
10. Lyman G, Cosler L, Kuderer N, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007;109:1011-8. (Pubitemid 46435378)
11. Zujewski J, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008;5:603-10.
12. IrvinW, Carey L. What is triple-negative breast cancer? Eur J Cancer 2008;44:2799-805.
13. Parise C, Bauer K, Brown M, et al. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009;6:593-602.
14. Fuchs-Young R, Shirley S, Lambertz I, et al. P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Res Treat 2010 Dec 30. [Epub ahead of print].
15. Tang P, Wang J, Hicks D, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 2010;9:978-82.
16. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008;112:731-6. (Pubitemid 351240566)
17. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med 2010;134:1697-701.